Oxford Nanopore Technologies (ONT) RBC Capital Markets Fireside chat summary

Strategy and execution

• Four pillars: customer-centric growth, focused innovation, disciplined execution, and a high-performance culture.

• Chief marketing and communications officer and chief development and product officer appointments fill key capability gaps in value proposition, evidence generation, product development, and portfolio simplification.

• A full management team is expected by Q4 2026, with further senior appointments anticipated; strategy operationalization is planned for 2027.

• Operational plan due with FY2026 results will cover the product roadmap, go-to-market refinements, governance, and potential organizational developments.

• 15–20 high-value applications prioritized as growth contributors over the next 4–5 years; some will be pursued sequentially, with examples expected during the coming year.

Biopharma

• Around 20 pharma companies are evaluating QC use; global biopharma accounts for over half of the group under discussion.

• GridION Q version two launched last week with added audit features for BLA filings; mRNA and Plasmid QC Test Packs have improved and cover most current customer requirements.

• Immediate QC focus is mRNA, AAV, and AVA vectors; sterility and other workflows remain in development to unlock further biopharma opportunity.

• The $4.1bn–$5.5bn biopharma market estimate combines bottom-up, risk-adjusted QC analysis with top-down research and development estimates.

• The mRNA QC Test Pack is listed at £2,000 per test, with commercial discounts expected for high-volume, multi-year commitments and deeper discounts for some early R&D use.

Clinical and partnerships

• Clinical grew 35% in H1; relative growth ranked rare disease first, infectious disease second, and oncology third, with a cited 30% diagnostic-yield uplift versus short-read technology in rare disease.

• Cepheid and bioMérieux partnerships target infectious-disease IVD; meaningful returns are expected no earlier than 3–5 years, preceded by manual workflows.

• Oncology and rare-disease LDT providers, including Natera, are validating tests; service-provider rollout could drive nearer-term adoption because LDTs can reach market faster than IVDs.

• QC customers need complete sample-to-report workflows; partnerships can supply automation, sample preparation, customized reporting, and bioinformatics while the full workflow is owned where appropriate.